Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Demeclocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | USP2 | O75604 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CASP7 | P55210 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demeclocycline SCHEMBL20716691 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL13085469 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL20952687 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL3252 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL5503953 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL2636809 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL29355123 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL29487284 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL6549174 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL41287 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 20575 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747611-A1 | OPTICAL ELECTRODE ANALYTE DETECTION SYSTEM AND METHODS OF USE | Vital Biosciences Inc. (CA) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| US-12636293-B2 | Methods of treating charcot-marie-tooth disease | CMTX BIOTECH INC. (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026105164-A1 | NON-AQUEOUS LIQUID FORMULATIONS OF TETRACYCLINE ANTIBIOTICS | ETICO LIFESCIENCES PRIVATE LIMITED (IN) | 2026-05-21 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4007582-B1 | ANTIBIOTICS IN COMBINATION WITH PHOTODYNAMIC THERAPY FOR USE IN A METHOD OF ENHANCING THE ANTIMICROBIAL ACTION OF SYSTEMICALLY ADMINISTERED ANTIBIOTICS | KOITE HEALTH OY (FI) | 2026-05-20 | — | — | EP | claimed |
| WO-2026090539-A1 | METHODS OF PREVENTING OR TREATING VESICANT-INDUCED INJURY | CMTX BIOTECH INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-5045538-A | Promoting protein synthesis in skeletal muscle systems | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1991-09-03 | — | — | US | claimed |
| EP-0380560-A4 | METHOD OF LOWERING INTRAOCULAR (EYE) PRESSURE | — | 1991-05-22 | — | — | EP | claimed |
| EP-0380560-A1 | USE OF TETRACYCLINE FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING THE INTRAOCULAR PRESSURE. | KRUPIN THEODORE (US) | 1990-08-08 | — | — | EP | claimed |
| US-4911924-A | Induction of antibiotic hypersensitivity in tetracycline-resistance microorganisms | UNIVERSITY OF NEW MEXICO (US) | 1990-03-27 | — | — | US | claimed |
| EP-0327295-A2 | Tetracycline dosage form | F.H. FAULDING & CO. LTD. (AU) | 1989-08-09 | — | — | EP | claimed |
| US-4853375-A | TREATING GLAUCOMA; TETRACYCLINE AND DERIVATIVES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1989-08-01 | — | — | US | claimed |
| WO-1989002270-A1 | METHOD OF LOWERING INTRAOCULAR (EYE) PRESSURE | KRUPIN THEODORE (US) | 1989-03-23 | — | — | WO | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0114003-A1 | Antiandrogen and antibiotic treatment of acne and pharmaceutical preparations therefor | Mortimer, Christopher Harry, Dr. (GB) | 1984-07-25 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |